Artelo Biosciences Chosen for Oral Presentation on the thirty second Annual ICRS Symposium in Galway, Eire


Artelo Biosciences

Artelo Biosciences

SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical firm targeted on modulating lipid-signaling pathways to develop therapies for folks dwelling with most cancers, ache, and neurological situations, introduced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, has been chosen for an oral presentation on the 32nd Worldwide Cannabinoid Analysis Society (ICRS) Symposium, on Sunday, June 26th. Dr. Sullivan can be presenting pre-clinical information associated to ART26.12, the Firm’s lead fatty acid binding protein 5 (FABP5) inhibitor. The Firm plans to supply a abstract of the analysis following the presentation. The ICRS Symposium is being held on the Bailey Allen Corridor on the Nationwide College of Eire, Galway, from June 25-30, 2022.

“We’re happy to take part on this necessary annual cannabinoid analysis convention and are excited to share our newest preclinical findings in ART26.12 improvement,” stated Gregory D. Gorgas, President and Chief Government Officer of Artelo Biosciences. “ART26.12 represents an necessary program in Artelo’s efforts to advance packages in most cancers and most cancers supportive care.”

As well as, the Firm will current the celebrated William A. Devane Younger Investigator of the 12 months Award on the ICRS Symposium to an impressive researcher on Wednesday, June 29th. Prior Younger Investigator awardees embody Professor Saoirse O’Sullivan and Physician Martin Kaczocha, Assistant Professor within the Division of Anesthesiology, Division of Biochemistry and Cell Biology, and the Institute of Chemical Biology and Drug Discovery at Stony Brook College and Scientific Advisor to Artelo Biosciences.

In regards to the Worldwide Cannabinoid Analysis Society
The Worldwide Cannabinoid Analysis Society (ICRS) is the premier world scientific affiliation with greater than 650 worldwide members from 40 international locations, all lively researchers within the area of endogenous, plant-derived, and artificial cannabinoids and associated bioactive lipids. Along with appearing as a supply for neutral data on hashish and the cannabinoids, the principle position of the ICRS is to supply an open discussion board for researchers to satisfy and talk about their analysis. events might comply with @ICRS_Society on Twitter and use #ICRS2022 for the newest assembly updates.

The ICRS William A. Devane Younger Investigator of the 12 months
In 2018, Artelo introduced a five-year dedication to sponsor the William A. Devane Younger Investigator of the 12 months award at annual ICRS Symposium. This award is a novel alternative to establish and showcase researchers who’ve proven dedication, perseverance, and talent in endocannabinoid system analysis. Previous recipients, Dr. Saoirse O’Sullivan, 2016 awardee, and Dr. Martin Kaczocha, 2017 awardee, are at the moment helping Artelo in advancing its product portfolio.

About ART26.12
Fatty Acid Binding Proteins (FABPs) are a household of intracellular proteins that chaperone lipids together with endocannabinoids and fatty acids. Varied inhibitors of FABPs could also be notably helpful for the therapy of particular cancers, neuropathic and nociceptive ache, and nervousness problems. ART26.12, Artelo’s lead FABP inhibitor compound, is a selective inhibitor of FABP5. Whereas growing our lead molecule for Chemotherapy-Induced Peripheral Neuropathy, extra compound(s) from our intensive library of potent and selective inhibitors of FABPs have been recognized and chosen for development in the direction of regulatory-enabling research in most cancers and different areas of high-unmet want the place inhibition of FABPs present important promise.

About Artelo Biosciences
Artelo Biosciences, Inc. is a scientific stage pharmaceutical firm devoted to the event and commercialization of proprietary therapeutics that modulate lipid-signaling pathways together with the endocannabinoid system. Artelo is advancing a portfolio of broadly relevant product candidates designed to handle important unmet wants in a number of ailments and situations, together with anorexia, most cancers, nervousness, ache, and irritation. Led by confirmed biopharmaceutical executives collaborating with extremely revered researchers and know-how specialists, the corporate applies vanguard scientific, regulatory, and industrial self-discipline to develop high-impact therapies. Extra data is on the market at www.artelobio.com and Twitter: @ArteloBio.

Ahead Trying Statements
This press launch accommodates sure forward-looking statements inside the that means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 and Non-public Securities Litigation Reform Act, as amended, together with these regarding the Firm’s product improvement, scientific and regulatory timelines, market alternative, aggressive place, doable or assumed future outcomes of operations, enterprise methods, potential development alternatives and different assertion which are predictive in nature. These forward-looking statements are based mostly on present expectations, estimates, forecasts and projections concerning the business and markets by which we function and administration’s present beliefs and assumptions. These statements could also be recognized by way of forward-looking expressions, together with, however not restricted to, “anticipate,” “anticipate,” “intend,” “plan,” “consider,” “estimate,” “potential,” “predict,” “challenge,” “ought to,” “would” and related expressions and the negatives of these phrases. These statements relate to future occasions or our monetary efficiency and contain recognized and unknown dangers, uncertainties, and different elements which can trigger precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements. Such elements embody these set forth within the Firm’s filings with the Securities and Change Fee, together with our skill to boost extra capital sooner or later. Potential traders are cautioned to not place undue reliance on such forward-looking statements, which converse solely as of the date of this press launch. The Firm undertakes no obligation to publicly replace any forward-looking assertion, whether or not because of new data, future occasions or in any other case, besides to the extent required by relevant securities legal guidelines.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Electronic mail: ARTL@crescendo-ir.com



Supply hyperlink